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Abstract
Background—The dominant invasive breast cancer histologic subtype, ductal carcinoma, shows 
intrinsic subtype diversity. However, lobular breast cancers are predominantly Luminal A. Both 
histologic subtypes show distinct relationships with patient and tumor characteristics, but it is 
unclear if these associations remain after accounting for intrinsic subtype.
Methods—Generalized linear models were used to estimate relative frequency differences 
(RFDs) and 95% confidence intervals (95% CIs) for the associations between age, race, tumor 
characteristics, immunohistochemistry (IHC) and RNA-based intrinsic subtype, TP53 status, and 
histologic subtype in the Carolina Breast Cancer Study (CBCS, n = 3,182) and The Cancer 
Genome Atlas (TCGA, n = 808).
Results—Relative to ductal tumors, lobular tumors were significantly more likely to be Luminal 
A [CBCS RNA RFD: 44.9%, 95% CI (39.6, 50.1); TCGA: RFD: 50.5%, 95% CI (43.9, 57.1)], 
were less frequent among young (≤ 50 years) and black women, were larger in size, low grade, 
less frequently had TP53 pathway defects, and were diagnosed at later stages. These associations 
persisted among Luminal A tumors (n = 242).
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Conclusions—While histology is strongly associated with molecular characteristics, histologic 
associations with age, race, size, grade, and stage persisted after restricting to Luminal A subtype. 
Histology may continue to be clinically relevant among Luminal A breast cancers.
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Introduction
Invasive breast cancer is composed of several distinct histologic subtypes. Ductal carcinoma 
is most commonly diagnosed, representing 60–80% of tumors and lobular carcinoma 
represents up to 15% of cases [1–3]. Previous clinical research has shown that compared to 
ductal carcinoma, lobular carcinoma tends to be diagnosed in women at older ages, presents 
as larger, lower grade tumors, is more frequently diagnosed at higher stage, and is associated 
with a higher rate of bilateral disease [1, 4–32]. While studies have shown that lobular 
tumors are often Luminal A intrinsic subtype, it is unclear if the observed associations 
between histologic subtype and tumor characteristics are similar in direction and magnitude 
when restricted to Luminal A tumors. As genomic tests become more widely utilized in 
clinical settings, it will be important to understand the relationship between histology and 
molecular subtype and whether both impact clinical outcomes.
A recent analysis from The Cancer Genome Atlas project (TCGA) found lobular tumors to 
be predominantly Luminal A intrinsic subtype and distinct from ductal tumors, which show 
a greater diversity of intrinsic subtypes [33]. However, TCGA samples are not racially 
diverse and do not span early stage of disease. Therefore, we examined the relationship 
between histologic and molecular subtypes in a population- based sample with larger 
numbers of black women, PAM50 subtype, a validated TP53 gene signature, and histologic 
subtype among participants in the Carolina Breast Cancer Study (1993–2013) and placed 
these results in context of the same associations estimated in TCGA.
Methods
Study populations
The present analysis includes 4,359 cases of invasive breast cancer from the Carolina Breast 
Cancer Study (CBCS), Phases 1–3 (1993–2013). The CBCS is a population-based study 
among women from North Carolina [34], designed to oversample younger women (aged < 
50 years at diagnosis) and black women [35]. Initiated in 1993, the CBCS recruited 
participants from 24 (Phase 1–2) and 44 (Phase 3) of the 100 North Carolina counties using 
rapid case ascertainment via the North Carolina Central Cancer Registry. After giving 
written informed consent, CBCS breast cancer cases were enrolled under an Institutional 
Review Board protocol approved at the University of North Carolina. CBCS eligibility 
criteria included being female, a first diagnosis of invasive or in situ (Phase 2 only) breast 
cancer, aged 20–74 years at diagnosis, and residence in specified counties. Only invasive 
cases were included in the current analysis. Participants provided consent to access tumor 
tissue blocks/slides and medical records from treatment centers.
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TCGA study population has been described previously [33, 36]. A total of 808 tumors from 
women with newly diagnosed invasive breast cancer were used in this analysis. Cases were 
enrolled at numerous medical institutions and provided informed consent for access to tumor 
tissue specimens, which were used for histologic subtype classification, RNA extraction, 
RNA sequencing, and other molecular assays. Age at diagnosis, race, tumor size, lymph 
node status, and stage of disease were abstracted from the medical records. TCGA data is 
publicly available [33, 36].
Histologic subtype
Eligible CBCS cases had invasive tumor tissue available for centralized pathology review by 
the study pathologist. Single histologic subtype tumors were ≥ 80% representative of a 
single histology and mixed tumors contained ≥ 20% of a second histologic subtype in a 
tumor of another dominant (< 80%) histologic subtype. The following histologic subtypes 
were included in the main analysis: ductal (n = 2,856) and lobular (n = 326). In select 
analyses, we also considered: mixed ductal/lobular (n = 473) and an ‘other’ category (n = 
704) including mixed ductal/non-lobular (n = 285), mucinous (n = 89), mixed ductal/
metaplastic (n = 63), metaplastic (n = 44), DCIS w/focal invasion (n = 44), undifferentiated 
high grade (n = 29), tubular (n = 23), micropapillary (n = 21), papillary (n = 19), medullary 
(n = 18), pleomorphic lobular (n = 17), anaplastic (n = 14), apocrine (n = 11), cribriform (n 
= 9), neuroendocrine (n = 3), other (n = 15). Cases with unknown (n = 99) or missing (n = 
376) histologic subtype were excluded.
In the TCGA, histologic subtype was available for all 808 women and was determined using 
clinical diagnostic criteria for histology applied by an expert pathologist committee [33]. A 
consensus ruling on histologic subtype was reached using the pathology reports and 
pathologist committee classification.
IHC-based 3-marker subtypes
For CBCS 1–2, estrogen receptor (ER) and progesterone receptor (PR) status was abstracted 
from medical records for approximately 80% of cases. The remaining cases with available 
tumor tissue had whole slide immunohistochem- istry (IHC) staining performed at UNC on 
tumor tissue samples. The percent positivity for estrogen receptor (ER) and progesterone 
receptor (PR) was determined by a study pathologist using contemporaneous clinical 
definitions. Human epidermal growth factor receptor 2 (HER2) IHC staining was performed 
at UNC; positivity was defined as membrane/membrane plus cytoplasmic staining classified 
as weak or greater intensity in ≥ 10% of tumor cells [37, 38].
In CBCS3, 98% of cases had ER, PR, and HER2 data abstracted from the medical records, 
serving as the primary data source to determine IHC subtype for CBCS3. For the remaining 
2% of cases without medical record data on ER, PR, and HER2, IHC staining was 
performed at UNC. For these 2% of cases, positivity cut points of ≥ 10% were used for ER 
and PR. HER2 positivity was defined as 3 + staining intensity [negative was defined as 0/1+ 
(equivocal cases with 2 + staining were excluded)] [39]. As Allott et al. [39] have described, 
for the 2% of CBCS3 cases without medical records ER, PR or HER2 data in this analysis, 
multiple tissue microarray (TMA) cores per case were stained for ER, PR, and HER2 and a 
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core-to-case collapsing method was applied to classify the case as positive/negative for each 
marker [39]. Percent positivity and staining intensity was determined by automated 
algorithms (Aperio Technologies).
In TCGA, ER and PR status were provided from Tissue Source Sites using 
contemporaneous positivity cut points. HER2 data was available for a majority of cases, but 
where unavailable was supplemented by TCGA using HER2 copy number rather than FISH 
data [33, 36].
Across CBCS and TCGA, ER, PR, and HER2 status, was used to create 3-marker IHC-
based subtypes defined as: Luminal A (ER+ or PR+ [any hormone receptor positive; HR+], 
HER2-), Luminal B (ER+ or PR+ [HR+], HER2+), Triple Negative (TN) (ER-, PR-, 
HER2-), and HER2+ (ER-, PR-, HER2+).
RNA-based intrinsic subtypes
For CBCS3, RNA counting (Nanostring) assays were carried out on a randomly sampled 
subset of available FFPE tumor tissue cores (n = 1,122) [39, 40]. RNA was isolated from 2, 
1.0-mm cores from the same FFPE block using the Qiagen RNeasy FFPE kit (cat# 73504). 
Samples lacking sufficient quality data (n = 101) or cases with > 1 tumor block (n = 8) were 
excluded. RNA-based intrinsic subtype was determined using the PAM50 gene signature 
described by Parker et al. [40]. Based on the highest Pearson correlation with a subtype-
defined centroid and each tumor was categorized into one of five intrinsic subtypes (Luminal 
A, Luminal B, HER2, Basal-like, Normal-like).
For TCGA, RNA was extracted from flash frozen tumor samples as previously described 
[33, 36]. Data accessed via https://tcgadata.nci.nih.gov/docs/publications/brca_2015/. 
PAM50 intrinsic subtype was determined using RNA gene expression data from microarrays 
or RNA sequencing data and categorized into one of the five intrinsic subtypes using an 
algorithm similar to that applied in CBCS3 [40, 41].
TP53 status
TP53 status was determined by immunohistochemistry (IHC) and RNA expression for 
CBCS3 cases as described elsewhere [42]. Briefly, IHC TP53 status was available for 
CBCS3 cases via IHC staining performed at the UNC Translational Pathology Laboratory. 
CBCS3 TMA construction with 1–4, 1 mm cores per participant, has been previously 
described [39]. A control TMA containing TP53 positive and negative breast tissue/cell lines 
was included in every staining run along with a negative control (no primary antibody).
Details of the TP53 scoring algorithm have been published [42, 43]. Briefly, TP53 staining 
was measured with the Aperio Nuclearv9 algorithm by quantifying tumor cel-lularity and 
was combined with the Genie Histology Pattern Recognition tool to classify the number of 
tumor and normal epithelial cells per core, allowing for tumor cell enrichment. To determine 
the average percent positivity, a method of core-to-case collapsing [39] and a percent-
positivity weighting method [42, 43] were employed. Weighted percent TP53 positivity was 
negative/wild-type (< 10%) or positive/mutant (≥ 10%).
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RNA-based TP53 status was determined for CBCS3 cases by detection of pathway 
deficiencies. In addition to the PAM50 genes, the Nanostring probe set contained 52 genes 
for a previously validated TP53 signature [41], which is independent of intrinsic subtype and 
classifies tumors as TP53 mutant-like or wild-type-like based on a similarity-to-centroid 
approach (Pearson coefficient) [41]. RNA-based TP53 status was available in TCGA. TP53 
status (mutant-like or wild-type-like), as determined by the aforementioned TP53 gene 
signature, was determined using RNA gene expression data from microarrays in the same 
manner described above for CBCS3 [40, 41].
Statistical analysis
Generalized linear models were used to estimate relative frequency differences (RFDs) and 
95% confidence intervals (95% CIs) as the measure of association between age, race, tumor 
characteristics, IHC subtype, intrinsic subtype, TP53 status and histologic subtype [44]. In 
CBCS1–3, unweighted sample size counts are presented alongside weighted percentages to 
account for the CBCS sampling design. The following variables were studied in association 
with histologic subtype in CBCS and TCGA: age (≤ 50, > 50), race [CBCS: self-reported 
black, non-black (> 98% white, 2% other (referred to as white); TCGA: black and white 
(other races were excluded in race-specific analyses due to low sample sizes)], combined 
tumor grade (CBCS1/3 only) (low-intermediate, high), AJCC stage of disease (I/II, III/IV), 
lymph node status (positive, negative), tumor size (≤ 2 cm, > 2 cm), ER (negative/positive), 
PR(negative/positive), HER2 (negative/positive), 3-marker IHC-based subtype, PAM50 
intrinsic breast cancer subtype (excluding Normal-like subtype), and TP53 status (IHC: 
negative/wild-type, positive/mutant; RNA: mutant-like, wild-type-like). Sample percentages 
and generalized linear model analyses were performed in SAS v9.4 (SAS Institute, Cary, 
NC). Graphs were constructed using GraphPad Prism v7.02 for Windows (GraphPad 
Software, La Jolla, CA). p values were produced for a two-sided test with an alpha of 0.05 
for statistical significance.
Results
Lobular characteristics in CBCS and TCGA
IHC-based and RNA-based intrinsic subtype distributions by histologic subtype, are 
presented in Fig. 1. Histologic distributions for CBCS3 and TCGA were similar, but TCGA 
had a slightly higher percentage of lobular tumors (CBCS; 9%; TCGA:15%) and a lower 
proportion of mixed tumors (CBCS: 16%; TCGA: 12%).
Compared to ductal tumors, lobular tumors displayed consistent differences in patient and 
tumor characteristics in CBCS and TCGA (Table 1). Associations between histology and 
age and race were weak, with black women and women ≤ 50 years of age less likely to be 
diagnosed with lobular disease in both studies. Compared to ductal, lobular tumors tended to 
be larger (CBCS Lobular relative frequency difference (RFD) (> 2 cm vs ≤ 2 cm): 14.0%, 
95% CI [10.7, 17.4]), lower grade (CBCS Lobular RFD [high vs. low-intermediate]: - 
43.4%, 95% CI [- 45.2, - 41.6]), and higher stage (CBCS Lobular RFD [III/IV vs. I/II]: 12.6, 
95% CI [9.7, 15.4]). In CBCS and TCGA, lobular tumors were less frequently ER-, PR-, and 
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HER2+. The magnitude and direction of RFDs for the associations between patient and 
tumor characteristics and histologic subtypes were similar in CBCS and TCGA (Table 1).
Based on a TCGA report of fewer TP53 DNA mutations among lobular tumors relative to 
ductal tumors [33], we assessed the distribution of TP53 status by histologic subtype in 
CBCS (Table 2). We evaluated TP53 mutant status by IHC (CBCS3) and by RNA (CBCS3 
and TCGA). Compared to ductal, lobular tumors were less likely to have TP53 mutant status 
(CBCS3: IHC mutant vs wild-type RFD: - 21.0%; 95% CI [- 24.4, - 17.6]; RNA mutant-like 
vs wild- type-like RFD: - 34.5% [- 39.5, - 29.4]) with a slightly larger magnitude association 
for lobular tumors in TCGA (RNA mutant-like vs wild-type-like RFD: - 41.8%; 95% CI [- 
50.9, - 32.8]) (results not shown).
Molecular subtype by RNA and IHC
We observed few differences in molecular subtype distributions within histologic subtypes 
between CBCS and TCGA. Supplemental Fig. 1 displays the distributions of Luminal A and 
Triple Negative (TN)/Basal-like tumors by lobular and ductal histologic subtype and by 
study. Lobular tumors were predominantly Luminal A and proportions were similar by 
molecular subtyping method and study (CBCS IHC [Luminal A: HR+/HER2-]: 89%, RNA: 
84%; TCGA IHC [Luminal A: HR+/HER2-]: 86%, RNA: 92%). Ductal tumors displayed 
more diversity in molecular subtype than lobular tumors. Proportions of ductal tumors with 
Luminal A subtype were similar between studies, but varied by technical method with lower 
percentages of ductal tumors classified as Luminal A by RNA than by IHC (Luminal A: HR
+/HER2-) in both CBCS3 and TCGA (CBCS IHC: 58%, RNA: 39%; TCGA IHC 55%, 
RNA:42%). Ductal tumors from CBCS had higher proportions of TN/Basal-like subtype 
than TCGA by IHC and RNA (CBCS IHC: 26%, RNA: 27%; TCGA IHC: 20%, RNA: 
23%).
We observed more pronounced differences in intrinsic subtype distribution according to 
technical method. The RFD and 95% CI for Luminal A compared to Non-Luminal A 
subtypes (IHC: Luminal B [HR+/HER2+], TN, and HER2+; RNA, PAM50: Luminal B, 
Basal-like, HER2- enriched) among lobular compared to ductal tumors are presented in 
Supplemental Fig. 2. Lobular tumors were more likely to be classified as Luminal A (IHC 
subtype: HR+/HER2-), with similar magnitude RFDs in CBCS1–3 and TCGA (CBCS: RFD 
[LumA vs. Non-LumA]: 30.9%, 95% CI: [28.6, 33.2]; TCGA: RFD 30.8%, 95% CI: [21.1, 
40.4]). The same association held for Luminal A RNA-based subtype, but the magnitude of 
effect was stronger (CBCS: RFD [LumA vs. Non-LumA]: 44.9%, 95% CI [39.6, 50.1]); 
TCGA: RFD: 50.5%, 95% CI [43.9, 57.1]). Thus, 3-marker IHC subtype results attenuated 
the association between histology and Luminal A subtype.
Histologic associations among Luminal A tumors
Analyses were performed among Luminal A tumors to determine if the observed 
associations between histologic subtype and tumor characteristics, race, and age persisted 
after accounting for intrinsic subtype (Table 2). When restricted to PAM50 Luminal A 
subtype, differences persisted for race and age with black and younger women less likely to 
be diagnosed with lobular as compared to ductal disease, and these estimates were similar to 
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those observed among tumors of all PAM50 subtypes. Similarly, in RNA analyses restricted 
to Luminal A subtype, lobular tumors remained larger in size, less likely to be high grade, 
and were diagnosed at higher stages of disease than ductal tumors. Associations for tumor 
characteristics and histologic subtype were similar in magnitude and direction by 3-marker 
IHC-based Luminal A subtype in CBCS1–3 (results not shown). Ductal and lobular tumors 
displayed similar differences in TP53 mutant status when determined by IHC and RNA.
Discussion
Characteristics of lobular tumors were quantitatively different from those of ductal tumors in 
CBCS and TCGA. In both studies, lobular tumors were significantly more likely to be 
Luminal A, both IHC- and RNA-defined, and have lower frequencies of TP53 pathway 
defects than ductal tumors. As previously reported, we found lobular disease to be more 
common among older and white women [4, 6, 10, 11, 45] more likely to be low-intermediate 
tumor grade, larger tumor size, and diagnosed at later stage of disease [1, 4, 6, 9–11, 14, 16, 
17, 19, 22–24, 33, 37, 46–50]. However, we show that the associations between lobular 
subtype and patient/ tumor characteristics, with the exception of TP53 status, persisted 
among Luminal A subtype only, suggesting that histology contributes to these observed 
associations even after restricting to a single, and the dominant, molecular subtype.
We observed associations that were quantitatively similar between two studies (CBCS and 
TCGA), but found that associations varied somewhat by technical method. In our study, the 
RFD for Luminal A subtype was 31% (comparing lobular to ductal) by IHC, but was 45% 
and 51% by RNA (CBCS3 and TCGA, respectively). In a sample of 75 lobular tumors from 
the I-SPY trial, Lips et al. (2012) determined PAM50 subtypes and reported an RFD of 44% 
for Luminal A subtype among lobular compared to ductal tumors, similar to our findings 
[50]. Other studies using IHC have reported RFDs for Luminal A subtype among lobular 
compared to ductal tumors ranging from 6 to 39%, reflecting tremendous molecular 
variability in the tumors studied [14, 16, 19, 22, 37, 47–49, 51, 52]. Proportions of Luminal 
A ductal tumors were also different between IHC subtype and RNA subtype data, suggesting 
RNA subtyping may be important for understanding associations between intrinsic subtype 
and histology.
In our study, we observed higher proportions of TP53 mutant-like tumors (RNA) than TP53 
accumulation (IHC) in each histologic subtype. Compared to ductal tumors, lobular tumors 
were less frequently TP53 mutant by IHC, as previously reported [4, 10, 11], and less 
frequently TP53 mutantlike by RNA in CBCS3 and TCGA. Nearly 50% of CBCS3 ductal 
tumors were TP53 mutant-like by RNA, whereas only 13% of lobular tumors showed the 
same molecular profile. This difference was also pronounced in TCGA, where the RFD for 
TP53 mutation among lobular (versus ductal) was greater than 40% (results not shown). 
However, when we restricted our analyses to Luminal A subtype tumors, we observed very 
low frequencies of either ductal or lobular tumors that were TP53 mutant by IHC or mutant-
like by RNA suggesting that TP53 status may be largely associated with molecular, rather 
than histologic subtype.
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Our study should be interpreted in light of some limitations. We used centralized pathology 
review to classify tumors as a pure histologic subtype if < 80% of a dominant histologic 
subtype was present. Classification rules for histologic subtypes vary and a uniform 
definition has not been established. In TCGA, an expert panel sought consensus for lobular 
versus ductal carcinoma and all discrepancies were adjudicated. These differences in 
classification could explain the differences histologic subtype frequencies between the two 
studies [33]. However, overall direction of each association was very similar between the 
two studies for all patient and tumor characteristics examined. Due to low sample sizes of 
lobular tumors with non-Luminal A subtypes, we were unable to examine lobular 
associations with tumor and patient characteristics among molecular subtypes other than 
Luminal A. Likewise, we were unable to study molecular characteristics of the rare 
histologic subtypes diagnosed in less than 2% of cases in CBCS. Rare histologic and 
molecular subtype combinations will likely require large, consortia- based investigations.
To conclude, patterns of association between lobular tumors and patient and tumor 
characteristics were similar when restricted to Luminal A intrinsic subtype, suggesting 
histology reflects some robust biological differences. Future research may leverage the 
molecular differences between lobular and ductal tumors to improve classification and 
prognostication.
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a Histologic subtype and IHC subtype distributions in CBCS1–3. b Histologic and PAM50 
intrinsic subtype distributions in CBCS3. c Histologic subtype and IHC subtype distributions 
in TCGA. d Histologic and PAM50 intrinsic subtype distributions in TCGA
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